News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novate Medical Release: The 1yr Results Of The SENTRY Clinical Trial Were Presented At The VIVA Physicians’ Congress



9/12/2017 11:17:46 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
12th September 2017 - The 1yr results of the SENTRY clinical trial were presented by its Principal Investigator, Michael Dake MD (Stanford Uni, Ca) today at the VIVA Physicians’ congress in Las Vegas, NV.

SENTRY is a prospective, single-arm, multi-centre registry trial in which the safety and effectiveness of the world’s first bioconvertible inferior vena cava (IVC) filter, Sentry (Novate Medical Ltd. Galway, Ireland) was studied. The Sentry is a new generation of IVC filter designed to provide protection from pulmonary embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen, obviating the need to retrieve and addressing the typical filter-related complications of existing IVC filters. 129 patients requiring temporary protection against PE were enrolled across 23 sites in the US, Europe and Chile. The rate of new symptomatic PE through 12 months was 0% (0/129). There were no instances of filter tilting, migration, embolization, fracture, or IVC perforation through 12 months, and there were no filter-related deaths. The rate of successful filter bioconversion was 95.7% (110/115) at 6 months and 96.4% (106/110) at 12 months; this is higher than the majority of published IVC filter retrieval rates. The Sentry IVC filter received FDA 510(k) clearance in February 2017.

Dr Dake commented “The SENTRY 1yr results are compelling; a 0% PE rate and no filter-related complications show that the Sentry IVC filter represents an important new development in the prevention of PE.”

Paul Bateman, Novate’s CEO added “We are enormously grateful to Dr Dake and all of the SENTRY investigational teams for their contribution to such a significant study. These data for this new generation of IVC filter marks a paradigm shift in the prevention of PE”

-ENDS-

About Novate Medical

Based in Galway, Ireland, Novate Medical has developed Sentry, the world’s first bioconvertible inferior vena cava (IVC) filter for the prevention of pulmonary embolism (PE) in patients at transient PE risk. The Sentry IVC filter does not require retrieval and addresses many of the known complications associated with currently available devices.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES